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INTRODUCTION
Metabolic syndrome was re-introduced in 1988 by Reaven,
who suggested that insulin resistance and compensatory hy-
perinsulinemia underlie the clustering of cardiovascular risk
factors, including glucose intolerance, hypertension, elevated
serum triglycerides, low serum HDL cholesterol, and central
obesity (1). Recently, the World Health Organization (WHO)
(2) and the National Cholesterol Education Program (NCEP)
expert panel (3) proposed working definitions for metabolic
syndrome.
Insulin resistance is a reduced physiological response of the
peripheral tissues to the action of insulin and is one of the
major causes of type 2 diabetes (4). Many studies have reported
that insulin resistance and hyperinsulinemia significantly in-
crease cardiovascular disease (CVD) morbidity and mortality
(5-7). Therefore, a reliable measure of insulin resistance is im-
portant for investigating the link between insulin resistance
and metabolic syndrome. The most reliable reference meth-
ods for measuring insulin sensitivity in vivo are the hyper-
insulinemic euglycemic clamp (8) and minimal-model anal-
ysis (MINMOD) of frequently sampled insulin levels during
an intravenous glucose tolerance test (9, 10), but these meth-
ods are time-consuming, invasive, expensive, and technically
difficult to apply in a clinical setting or for large populations.
For this reason, simpler, less-invasive techniques of deter-
mining insulin resistance, based on measuring fasting serum
insulin and glucose, have been developed. The homeostasis
model for insulin resistance (HOMA-IR) (11, 12) and the
quantitative insulin sensitivity check index (QUICKI) (13)
are the most commonly used surrogate measures and provide
a reliable alternative to the glucose clamp. Many studies on
reliable, simple, indirect methods for detecting insulin resis-
tance in the general population have been reported (14-20).
Although the prevalence of metabolic syndrome in Korean
adults has been investigated recently (21-26), no study has
examined the cutoff values of surrogate measures of insulin
resistance for increased metabolic syndrome in Korean adults.
Therefore, we investigated the cutoff values of surrogate mea-
sures of insulin resistance for identifying metabolic syndrome
in the Korean adults.
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Cutoff Values of Surrogate Measures of Insulin Resistance for
Metabolic Syndrome in Korean Non-diabetic Adults
We investigated the cutoff values of surrogate of insulin resistance for diagnosing
metabolic syndrome in Korean adults. The data from 976 non-diabetic individuals
(484 men and 492 women) aged 30-79 yr were analyzed. We determined the odds
ratios for the prevalence of metabolic syndrome according to the quartiles of fasting
insulin, homeostasis model for insulin resistance (HOMA-IR), and quantitative insulin
sensitivity check index (QUICKI) as independent variables, while adjusting for age,
sex, and body mass index. The cutoff values of fasting insulin, HOMA-IR, and QUICKI
were estimated by the areas under the receiver-operating characteristic (ROC) curves.
The cutoff points for defining insulin resistance are a fasting insulin level of 12.94
U/mL, HOMA-IR=3.04 as the 75th percentile value, and QUICKI=0.32 as the 25th
percentile value. Compared with the lowest quartile, the adjusted odds ratios for the
prevalence of metabolic syndrome in the highest quartiles of fasting insulin, HOMA-
IR, and QUICKI were 1.95 (1.26-3.01), 2.27 (1.45-3.56), and 2.27 (1.45-3.56), res-
pectively. The respective cutoff values for fasting serum insulin, HOMA-IR, and QUIC-
KI by ROC analysis were 10.57  U/mL (sensitivity 58.5%, specificity 66.8%), 2.34
(sensitivity 62.8%, specificity 65.7%), and 0.33 (sensitivity 61.2%, specificity 66.8%).
Fasting insulin, HOMA-IR, and QUICKI can be used as surrogate measures of insulin
resistance in Korean non-diabetic adults.
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MATERIALS AND METHODS
Subjects
This study was performed as a part of the Korean Metabolic
Syndrome Study, which is evaluating the role of metabolic
syndrome as a risk factor for cardiovascular disease in Korean
adults (27). The study protocol was approved by the ethics
committee of the Severance Hospital at Yonsei University,
and informed consent was obtained from each participant.
We measured the metabolic profile, cardiovascular risk fac-
tors, and carotid intima-media thickness (IMT) of 1,230 men
and women aged 30 to 79 yr old. These measurements were
made over a 3 month period (April to June, 2001) at a health
screening center in Seoul, Korea. All the participants were
healthy, independently functioning individuals who were at
the health center to undergo screening tests. Of the 1,230
initial volunteers, 1,207 men and women completed anthro-
pometric measurements, serum biochemistry, and carotid
IMT measurements. Individuals who had diabetes (fasting
serum glucose ≥126 mg/dL or currently using antidiabetic
medication; n=115) or had a missing value for insulin (n=
118) were excluded from the analysis. Ultimately, 976 sub-
jects (484 men and 492 women) were used in the analyses.
Clinical and laboratory data
Trained nurses interviewed all the participants and obtained
their medical history, family history of chronic disease, and
information on life style factors, using a standardized ques-
tionnaire. The weight and height of each participant was
measured while the subject was clothed only in a light gown,
and the body mass index (BMI) was calculated as body weight
divided by height squared (kg/m2). Waist circumference was
measured at the level midway between the lowest rib margin
and the iliac crest; hip circumference was measured at the
widest level over the greater trochanters in a standing posi-
tion, by the same examiner. The participants were required
to rest for at least 5 min before having their blood pressure
checked twice at an interval of at least 1 min. The mean value
of these two measurements was used for the analyses.
Fasting blood samples were collected from an antecubital
vein in plain tubes early morning after an 8 hr fast. Blood
glucose was estimated using a glucose oxidase method (747
automatic analyzer, Hitachi, Tokyo, Japan), and fasting glu-
cose was evaluated according to the new criteria of the Amer-
ican Diabetes Association; the subjects were defined as hav-
ing diabetes mellitus if the fasting serum glucose (FSG) was
≥7.0 mM/L, as impaired fasting glucose if the FSG was
6.1-6.9 mM/L, and as normal if the FSG was <6.1 mM/L
(28). Serum total cholesterol, HDL-cholesterol, and triglyc-
erides were determined by an enzymatic colorimetric method
using an automatic analyzer (Au5200, Olympus, Tokyo,
Japan), and LDL-cholesterol was calculated using Friedewald’s
equation.
Assessing insulin resistance
Serum insulin was estimated using a radioimmunoassay
(Linco Research Inc., St. Louis, MO, U.S.A.) with a 4.0%
interassay coefficient of variation; this method does not cross-
react with proinsulin. Two indirect indices for assessing insulin
resistance were calculated. HOMA-IR uses the formula des-
cribed by Matthews et al.: fasting insulin ( U/mL)×fasting
glucose (mM/L)/22.5 (11). The QUICKI index is based on
the logarithmic transformation: 1/(log fasting insulin [ U/
mL]+log fasting glucose [mg/dL]) (13).
Definition of metabolic syndrome
We used the NCEP Adult Treatment Panel (ATP) III defi-
nition of metabolic syndrome (3). We used the waist circum-
ference criterion of the Asia-Pacific Region instead of the orig-
inal criterion (29). The modified NCEP definition required
at least three of the following: 1) increased waist circumfer-
ence (>90 cm in men and >80 cm in women), 2) high trigly-
cerides (≥1.7 mM/L, [150 mg/dL], 3) low HDL cholesterol
(<1.04 mM/L [40 mg/dL] in men and <1.29 mM/L [50 mg/
dL] in women), 4) high blood pressure (≥130/85 mmHg or
current antihypertensive medications), and 5) high fasting
glucose (≥6.1 mM/L [110 mg/dL]).
Statistical analysis
The data in Table 1 are given as the mean (SD). The clini-
cal and metabolic characteristics of the subjects according to
gender were analyzed using an independent sample I-test.
Multiple logistic regression analyses were used to estimate the
Data are means (SD). *p<0.01, 
� p<0.05 between men and women.
Characteristic Men Women Total
Number of subjects 484 492 976
Age (yr)* 50.6 (10.6) 52.7 (9.5) 51.7 (10.1)
BMI (kg/m
2)
� 24.5 (2.7) 24.9 (3.3) 24.7 (3.0)
Waist circumference (cm)* 86.2 (7.3) 82.1 (8.3) 84.1 (8.1)
Systolic blood pressure 129.5 (17.3) 130.8 (19.7) 130.2 (18.6)
(mmHg)
Diastolic blood pressure  80.3 (11.7) 80.0 (12.8) 80.1 (12.3)
(mmHg)
Total cholesterol (mM/L)* 5.15 (0.84) 5.34 (0.95) 5.24 (0.90)
Triglyceride (mM/L)* 2.11 (1.42) 1.63 (1.26) 1.87 (1.36)
HDL cholesterol (mM/L) * 1.13 (0.25) 1.32 (0.36) 1.22 (0.32)
Fasting serum glucose  5.26 (0.54) 5.10 (0.51) 5.18 (0.53)
(mM/L)*
Fasting serum insulin 10.9 (6.0) 11.0 (6.6) 11.0 (6.3)
( U/mL)
HOMA-IR 2.59 (1.57) 2.52 (1.57) 2.55 (1.57)
QUICKI 0.34 (0.03) 0.34 (0.03) 0.34 (0.03)
Table 1. General characteristics of the study subjectsCutoff Values of Insulin Resistance 697
odds ratios for the prevalence of metabolic syndrome accord-
ing to the quartiles of fasting insulin, HOMA-IR, and QUIC-
KI as independent variables, while adjusting for age, sex, and
BMI. Pearson’s correlation coefficients between the surrogate
markers of insulin resistance (fasting insulin, HOMA-IR,
and QUICKI) and the components of metabolic syndrome
adjusted for age and sex were analyzed. The areas under the
receiver-operating characteristic (ROC) curves for fasting
insulin, HOMA-IR, and QUICKI for increased likelihood
of metabolic syndrome were compared, and the cutoff values
for fasting insulin, HOMA-IR, and QUICKI were estimated.
The mean and SD of fasting insulin, HOMA-IR, and QUIC-
KI were compared according to the number of components
of metabolic syndrome using the modified NCEP criteria,
while adjusting for age and sex. The statistical analysis was
conducted using the program SPSS for Windows (version
11, SPSS Inc., Chicago, IL, U.S.A.), and p<0.05 was consid-
ered statistically significant.
RESULTS
The general characteristics of the 976 subjects, comprising
484 men and 492 women, are shown in Table 1 and Fig. 1.
Women were older and had a higher BMI than men, but had
a smaller waist circumference than men. Total cholesterol and
HDL cholesterol were higher in women, while triglycerides
were higher in men. Fasting insulin, HOMA-IR, and QUICKI
were not significantly different between men and women.
Table 2 shows the odds ratios for the prevalence of meta-
bolic syndrome according to the quartiles of fasting insulin,
HOMA-IR, and QUICKI as independent variables. The cut-
off point defining insulin resistance was a fasting insulin level
of 12.94  U/mL, HOMA-IR=3.04 as the 75th percentile
value, and QUICKI=0.32 as the 25th percentile value. Com-
pared with the lowest quartile of fasting insulin level, the
crude and adjusted odds ratios for the prevalence of metabolic
syndrome in the highest quartile were 3.76 (2.54-5.57) and
1.95 (1.26-3.01), respectively, which were significantly in-
creased according to the increased quartile of fasting insulin.
Similarly, the crude and adjusted odds ratios for the preva-
lence of metabolic syndrome among the highest quartile of
HOMA-IR were 4.48 (2.98-6.71) and 2.27 (1.45-3.56),
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Fig. 1. Distribution of age, body mass index, fasting glucose and fasting insulin of study subjects. 
Data are given as the number, interquartile range, OR, and 95% confi-
dence interval. *Adjusted for age, sex, and BMI.
Para-
meter
No.
Interquar-
tile range
Preva-
lence
(%)
Crude
OR 95% CI
Adjusted*
OR 95% CI
Insulin
1 244 -7.12 22.1 1.00 1.00
2 244 7.12-9.58 22.1 1.00 0.65-1.53 0.84 0.53-1.32
3 244 9.58-12.94 37.3 2.09 1.41-3.12 1.55 1.01-2.38
4 244 12.94- 51.6 3.76 2.54-5.57 1.95 1.26-3.01
HOMA-IR
1 244 -1.62 19.3 1.00 1.00
2 244 1.62-2.19 23.0 1.25 0.81-1.93 1.05 0.66-1.66
3 244 2.19-3.04 39.3 2.72 1.81-4.09 2.12 1.37-3.28
4 244 3.04- 51.6 4.48 2.98-6.71 2.27 1.45-3.56
QUICKI
1 244 -0.32 51.6 4.48 2.98-6.71 2.27 1.45-3.56
2 244 0.32-0.34 39.3 2.72 1.81-4.09 2.12 1.37-3.28
3 244 0.34-0.36 23.0 1.25 0.81-1.93 1.05 0.66-1.66
4 244 0.36- 19.3 1.00 1.00
Table 2. The prevalence and odds ratios (OR) of metabolic syn-
drome according to the quartiles of fasting serum insulin, HOMA-
IR, and QUICKI
Data are Pearson’s correlation (r) coefficients adjusted for age and sex
and standardized coefficients (beta) using multivariate regression anal-
ysis. *p<0.001, 
� p<0.005.
Component
Insulin
Univa-
riate (r)
Multiva-
riate 
(beta)
QUICKI
Univa-
riate (r)
Multiva-
riate 
(beta)
HOMA-IR
Univa-
riate (r)
Multiva-
riate 
(beta)
Fasting glucose 0.172* 0.114* 0.334* 0.283* -0.340* -0.285*
Systolic blood  0.102
� -0.059 0.117* -0.053 -0.168* -0.057
pressure
Diastolic blood  0.109
� 0.067 0.117* 0.057 -0.181* -0.131
�
pressure
Triglyceride 0.238* 0.158* 0.235* 0.151* -0.233* -0.149*
HDL cholesterol -0.094
� 0.031 -0.104
� 0.032 0.098
� -0.030
Waist circum- 0.377* 0.337* 0.381* 0.315* -0.372* -0.291*
ference
Table 3. Correlation between surrogate markers of insulin resis-
tance and the components of metabolic syndrome698 S. Lee, S. Choi, H.J. Kim, et al.
respectively, which were also significantly increased accord-
ing to the increased quartile of HOMA-IR. The odds ratio
for QUICKI was the same as that for HOMA-IR, which was
higher than that for fasting insulin.
Table 3 shows the relationship between the surrogate mar-
kers of insulin resistance (fasting insulin, HOMA-IR, and
QUICKI) and the components of metabolic syndrome adjust-
ed for age and sex. All the values of the components of meta-
bolic syndrome were significantly related to fasting insulin,
HOMA-IR, and QUICKI. HOMA-IR was most strongly
correlated with waist circumference and HDL cholesterol.
The areas under the ROC curves for fasting insulin, HOMA-
IR, and QUICKI are shown as Fig. 2. The areas under the
ROC curves (95% CI) for the three parameters were 0.656
(0.625-0.685), 0.672 (0.641-0.701), and 0.671 (0.641-0.701),
respectively. The cutoff values for fasting serum insulin, HO-
MA-IR, and QUICKI were 10.57  U/mL (sensitivity 58.5%,
specificity 66.8%), 2.34 (sensitivity 62.8%, specificity 65.7%),
and 0.33 (sensitivity 61.2%, specificity 66.8%) (p<0.001),
respectively. 
DISCUSSION
In this study, we demonstrated that fasting insulin, HOMA-
IR, and QUICKI are simple, yet reliable, methods for detecting
insulin resistance in the Korean non-diabetic general popu-
lation. Insulin resistance was strongly associated with meta-
bolic syndrome. We also proposed cutoff values for fasting
insulin, HOMA-IR, and QUICKI for predicting an increased
likelihood of metabolic syndrome in Korean non-diabetic
adults. The cutoff values for insulin resistance can be adopt-
ed for epidemiological studies, as well as in clinical practice.
The gold standard test for evaluating insulin resistance is
the euglycemic hyperinsulinemic clamp, but its use is lim-
ited to clinical practice owing to the time and cost involved
(8). Many studies have reported on several simple methods
for evaluating insulin resistance that can reduce time and cost
and are relatively accurate (11-13).
Fasting insulin levels are one of the simplest indirect indices
for diagnosing insulin resistance. Yeni-Komshian et al. reported
that the fasting plasma insulin concentration was significantly
correlated with the estimated insulin action (r=0.61, p<
0.001) (16), and Strumvoll et al. reported that the correla-
tion coefficient between fasting insulin and the insulin sen-
sitivity index (ISI) was remarkably similar to that between
ISI and the 120 min insulin (-0.59 vs. -0.62) (30), suggest-
ing that fasting insulin is a simple predictor of insulin resis-
tance. McAuley et al. suggested that fasting insulin alone was
as accurate at predicting insulin resistance in the normogly-
cemic population and that a fasting insulin level ≥12.2 U/
mL in normoglycemic individuals was a reliable test for insulin
resistance (17). In our study, the cutoff value of fasting insulin
for defining insulin resistance was 12.94  U/mL as the 75th
percentile in Korean non-diabetic adults, which is similar
to the 12  U/mL of Ascaso et al. (19). The cutoff value of
fasting insulin for increased metabolic syndrome in our study
was 10.57  U/mL, which is lower than the cutoff for insulin
resistance. Our cutoff value is similar to the results of Park
et al. (10.15  U/mL in men, 9.53  U/mL in women) for a
sample of 7,057 healthy Korean adults (21).
The HOMA-IR is a useful, validated method for evaluat-
ing insulin resistance (11, 12). Bonora et al. suggested that
the top quintile of the HOMA-IR, i.e., a value ≥2.77, had
isolated insulin resistance in subjects with no metabolic dis-
orders (14). In the Botnia study, Tripathy et al. found that
subjects with impaired fasting glucose were more insulin
resistant than subjects with normal glucose tolerance (HOMA-
IR, 2.64 vs. 1.73) (15). Yeni-Komshian et al. suggested that
the cutoff of HOMA-IR in 490 healthy non-diabetic volun-
teers based on determining the steady-state plasma glucose
was 2.7 (16). Ascaso et al. reported that the 75th percentile
value as the cutoff point for defining insulin resistance was
HOMA-IR=2.6 (19). In our study, the HOMA-IR was a
more reliable index of insulin resistance than the fasting insulin
level in Korean non-diabetic adults. The 75th percentile value
of HOMA-IR was 3.04, and the cutoff of the HOMA-IR for
increasing metabolic syndrome was 2.34. Other studies of
Korean populations have found that the mean HOMA-IR in
metabolic syndrome, impaired glucose tolerance, or type 2
diabetes was 3.0-3.5 (23, 31, 32) and that the cutoff value of
HOMA-IR for increased metabolic syndrome in healthy Kore-
an adults was 2.78 in men and 2.48 in women (21), which
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Fig. 2. Receiver-operating characteristic (ROC) curves for fasting
serum insulin, HOMA-IR, and QUICKI for increased metabolic
syndrome. The cutoff values for fasting serum insulin, HOMA-IR,
and QUICKI are 10.57  U/mL (sensitivity 58.5%, specificity 66.8
%), 2.34 (sensitivity 62.8%, specificity 65.7%), and 0.33 (sensitivity
61.2%, specificity 66.8%) (p<0.001, respectively). The areas under
the ROC curves (95% CI) for the parameters are 0.656 (0.625-
0.685), 0.672 (0.641-0.701), and 0.671 (0.641-0.701), respectively.
HOMA_IR
QUICKIis similar to our result.
The recently developed QUICKI by Katz et al. may be a
better surrogate measure of insulin resistance than HOMA-
IR (13). They reported that the overall correlation between
the gold standard SIclamp and QUICKI (r=0.78) was signifi-
cantly better than the overall correlation between SIclamp and
HOMA-IR (r=0.6). Hrebicek et al. found that adult patients
with QUICKI <0.357, which is the lower limit of the 95%
confidence limits in healthy persons, formed a group with
typical manifestations of metabolic syndrome (18). Ascaso
et al. found that the 25th percentile of QUICKI was 0.33
(19). Brady et al. suggested that the revised QUICKI based
on fasting insulin, glucose, and free fatty acids is most strongly
correlated with insulin sensitivity (Si) using the minimal
model, compared with QUICKI or HOMA-IR (r=0.67 vs.
0.51 vs. 0.50) (20). In our study, the 25th percentile value
of QUICKI was 0.32, and the cutoff of QUICKI for increased
metabolic syndrome was 0.33.
Recently, the International Diabetes Federation suggested
the new criteria for metabolic syndrome with necessity of
the diagnostic standard that could be used commonly world-
wide (33). Using this new criteria, the cutoff values of fasting
insulin, HOMA-IR, and QUICKI are 10.58  U/ mL, 2.38,
and 0.33, which are similar to the results of NCEP criteria.
Insulin resistance is an important risk factor for type 2 dia-
betes and cardiovascular disease. Yip et al. reported that, dur-
ing a 5 yr follow-up, 18% of the most insulin-resistant group
developed either high blood pressure or had a CVD event
and that insulin resistance or compensatory hyperinsuline-
mia predicted CVD events (6). In a 6 yr prospective follow-
up study of 208 healthy adults, Facchini et al. reported that
one-fifth of insulin-resistant individuals developed age-relat-
ed diseases, such as hypertension, coronary artery disease,
cerebral ischemia, cancer, and type 2 diabetes mellitus, while
none of the insulin-sensitive group developed any of these
diseases (7). They also stated that insulin resistance is a very
important factor for predicting the future occurrence of age-
related diseases, even in healthy adults. Huh et al. found that
strict therapy with a low-fat, low-calorie diet in patients with
coronary artery disease for 1 yr resulted in weight reduction,
improved lipid profiles and insulin resistance, and ultimately
improved coronary diameter stenosis (34). Therefore, they
suggested that improving insulin resistance reduced risk
factors and reversed coronary atherosclerosis.
In this study, we found that insulin resistance was strongly
associated with metabolic syndrome and its components,
especially with central obesity (waist circumference) and hy-
pertriglyceridemia. In addition, we found that metabolic
syndrome in Korean non-diabetic adults was increased at a
lower level of insulin resistance than the 75th percentile of
fasting insulin and HOMA-IR or the 25th percentile of QU-
ICKI. Consequently, we must be concerned with the early
detection of insulin resistance and metabolic syndrome in
clinical and epidemiological settings and with the preven-
tion of type 2 diabetes, dyslipidemia, hypertension, and car-
diovascular diseases.
This study has some limitations. First, the diagnosis of
insulin resistance was made based only on single test of fast-
ing blood glucose and insulin. Hyperinsulinemic-euglycemic
clamp were not performed to confirm the diagnosis of insulin
resistance. However, WHO recommended this method for
epidemiological study (2). Second, there were selection bias
and thus limitation of representative of Korean adults in this
study subjects. Third, although plasma glucose assay is highly
reproducible in different laboratories, insulin assay can vary
considerably, especially if antibodies cross-reacting with proin-
sulin are used (35). In our study, we used an human insulin-
specific radioimmunoassay with no significant cross-reactiv-
ity with proinsulin, thereby minimizing the interference on
surrogate measures by proinsulin.
In conclusion, fasting insulin, HOMA-IR, and QUICKI
can be used as surrogate measures of insulin resistance in
Korean non-diabetic adults. We suggest that the cutoff val-
ues of these simple methods can be applied to evaluate insulin
resistance and to predict metabolic syndrome in Korean non-
diabetic adults. Furthermore, we should monitor the healthy
insulin-resistant population to prevent ongoing cardiovascu-
lar diseases. Prospective follow-up data are needed to refine
the correlations of insulin resistance to metabolic syndrome
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